Annexin I is a glucocorticoid-induced mediator with anti-inflammatory activity in animal models of arthritis. We studied the effects of a bioactive annexin I peptide, ac 2–26, dexamethasone (DEX), and interleukin-1β (IL-1β) on phospholipase A₂ (PLA₂) and cyclooxygenase (COX) activities and prostaglandin E₂ (PGE₂) release in cultured human fibroblast-like synoviocytes (FLS). Annexin I binding sites on human osteoarthritic (OA) FLS were detected by ligand binding flow cytometry. PLA₂ activity was measured using ³H-arachidonic acid release, PGE₂ release and COX activity by ELISA, and COX2 content by flow cytometry. Annexin I binding sites were present on human OA FLS. Annexin I peptide ac 2–26 exerted a significant concentration-dependent inhibition of FLS constitutive PLA₂ activity, which was reversed by IL-1β. In contrast, DEX inhibited IL-1β-induced PLA₂ activity but not constitutive activity. DEX but not annexin I peptide inhibited IL-1β-induced PGE₂ release. COX activity and COX2 expression were significantly increased by IL-1β. Annexin I peptide demonstrated no inhibition of constitutive or IL-1β-induced COX activity. DEX exerted a concentration-dependent inhibition of IL-1β-induced but not constitutive COX activity. Uncoupling of inhibition of PLA₂ and COX by annexin I and DEX support the hypothesis that COX is rate-limiting for PGE₂ synthesis in FLS. The effect of annexin I but not DEX on constitutive PLA₂ activity suggests a glucocorticoid-independent role for annexin I in autoregulation of arachidonic acid production. The lack of effect of annexin I on cytokine-induced PGE₂ production suggests PGE₂-independent mechanisms for the anti-inflammatory effects of annexin I in vivo.

Key words: Annexin I, Dexamethasone, Synoviocytes, Eicosanoid generation

Introduction

Prostaglandins, such as prostaglandin E₂ (PGE₂), mediate the pain and edema associated with arthritis, leading to the widespread use of non-steroidal anti-inflammatory drugs in the treatment of arthritis. Within the arthritic synovial lesion, fibroblast-like synoviocytes (FLS) have been implicated as a primary source of PGE₂.¹ In eicosanoid generation, phospholipase A₂ (PLA₂) and cyclooxygenase (COX, or prostaglandin H synthase) have been described as important regulatory enzymes. The hydrolytic release of arachidonic acid from membrane phospholipids is initiated by PLA₂, and arachidonic acid is then catalysed by COX enzymes for the subsequent production of PGE₂. PLA₂ exists as a secretory group II isoform (sPLA₂) and an arachidonic acid-selective cytosolic form (cPLA₂).² Two isoforms of COX have also been identified: a constitutive (COX1) and a mitogen/growth factor-inducible (COX2) form.³ Studies in a COX2 gene knock-out animal model demonstrate that joint inflammation still persists in the absence of this enzyme.⁴ At present, the enzymatic events responsible for the enhanced production of PGE₂ in rheumatoid arthritis (RA) are not fully understood. Knowledge pertaining to which enzyme is rate-limiting in eicosanoid generation in synovium is not fully elucidated. It is known that expression of the cPLA₂ and COX2 are increased by interleukin-1β (IL-1β)⁵,⁶ and that this induction is inhibited by the anti-inflammatory action of dexamethasone (DEX).⁵,⁶,⁷

Annexin I (previously known as lipocortin-1) is a 37 kDa protein which belongs to a family of at least 13 structurally related proteins that bind to anionic phospholipids in a Ca²⁺-dependent manner.⁸ Annexin I was originally defined as a glucocorticoid-inducible inhibitor of PLA₂ activity.⁹ The concept that annexin I may modulate its anti-inflammatory actions via cell
surface binding sites has been suggested from the identification of extracellular annexin I binding sites on peripheral blood leukocytes. The involvement of annexin I in the regulation of joint inflammation has now been demonstrated in several rat models of arthritis, in which a range of biological actions extending beyond effects on PLA\_2 activity has been suggested. The possibility that annexin I has anti-inflammatory activity in human arthritis has not been previously explored. We sought to further define the effects of annexin I on PLA\_2, COX and prostaglandin production in human FLS, and use the known PLA\_2 inhibitory properties of annexin I to investigate the rate-limiting step in synoviocyte prostaglandin production.

**Materials and methods**

**Materials**

Annexin I ac 2–26 N-terminal derived peptide (acetyl-AMVSEFLKQAWFIENEEQEYVQTVK) was prepared by use of solid phase step-wise synthesis and obtained from Prof. Milton Hearn (Monash University, Clayton, Australia). Purity was more than 99% as determined by high-performance liquid chromatography. Annexin I monoclonal antibody 1B was produced from hybridoma cultures kindly donated by Dr J Browning, Biogen Inc., Cambridge, USA, and purified using saturated (50%) ammonium sulfate precipitation, protein A sepharose affinity chromatography. Affi-Gel 10 was purchased from Bio Rad, Australia. RPMI 1640 solution, sodium bicarbonate 7.5% solution, penicillin (5000 IU/ml)/streptomycin (5000 \( \mu \)g/ml), L-glutamine and 1 \( \times \) trypsin/ethylenediaminetetraacetic acid (EDTA) solution were purchased from ICN Biomedicals, USA. Human recombinant IL-1\( \beta \) (specific activity 5.95 \( \times \) 10\(^7\) U/mg), DEX, collagenase type II (specific activity > 125 U/mg), [5,6,8,9,11,12,14,15-H\]arachidonic acid, bovine serum albumin (BSA) and calcium chloride were purchased from Sigma, Australia. [5,6,8,9,11,12,14,15-\(^3\)H]arachidonic acid (specific activity 212 Ci/mmol, 1.0 mCi/ml) was purchased from Amersham International plc, Australia. DNase I from bovine pancreas (specific activity > 2000 U/mg) and dispase I grade II (specific activity > 0.5 U/mg) were purchased from Boehringer Mannheim, Australia. COX2 monoclonal antibody and positive isotype control mAb, IgG\(_1\), were purchased from Transduction Laboratories, USA. Normal human IgG was purchased from CSL Pty Ltd, Australia. Control mAb, IgG\(_2a\), fluoroisothiocyanate (FITC)-conjugated anti-mouse IgG was purchased from Silenus, Australia. PG\(_E2\) enzyme linked immuno assay (ELISA) kit was purchased from Neogen Corporation, USA. Ultima-gold scintillation fluid was purchased from Packard Instrument Company, Australia.

**Purification of annexin I protein**

Recombinant human annexin I, a generous gift from Dr Yuko Giga-Hama (Research Centre, Asahi Co. Ltd, Japan), was purified by affinity gel chromatography, as described by Sakata et al., using purified monoclonal mouse anti-human annexin I antibody. To confirm purification, samples of purified annexin I dissolved in sample buffer were separated on a 12% gel using SDS-polyacrylamide gel electrophoresis techniques. A single 37 kDa protein band was detected by western blotting using a specific anti-annexin I mAb.

**Isolation and culture of FLS**

FLS were obtained from synovium of osteoarthritic (OA) patients (n = 8) undergoing joint replacement surgery. All patients satisfied the American College of Rheumatology criteria for the classification of OA. FLS were isolated and cultured as described by Koch. In brief, the synovial-lining tissue was dissected and minced into 2–3 mm pieces and rotated in 10 ml/2 g of enzyme solution containing 2.4 mg/ml dispase (grade II, 5 U/mg), 1 mg/ml collagenase (type II) and 1 mg/ml DNase (type I) in Ca\(^{2+}\) and Mg\(^{2+}\) free Hank’s balanced saline solution. FLS were cultured in 10 cm culture plates in RPMI/10% foetal calf serum at 37\(^\circ\)C in a 5% CO\(_2\) humidified incubator. Cells at 3rd passage were more than 99% FLS, as demonstrated by dendritic, spindle morphology, and negative staining for the pan-leukocyte antigen CD45 by flow cytometry. Cells were used between passages 4 and 9. For all experiments, FLS were seeded at 1 \( \times \) 10\(^5\) cells per well in 24-well culture plates in RPMI/10% FCS and allowed to adhere overnight, prior to medium being replaced with RPMI/0.1% BSA for experimental purposes. This study was approved by the institutional ethics board.

**Detection of annexin I binding sites**

FLS were examined using a method that detects specific saturable annexin I binding sites, as described by Perretti et al. Briefly, surface bound annexin I was removed by washing with 1 mM EDTA/PBS. FLS were then washed with 0.1% BSA/phosphate buffered saline (PBS)/1.3 mM CaCl\(_2\) and resuspended in 20 \( \mu \)l 0.2% BSA/RPMI at 4\(^\circ\)C and incubated with 0–10 \( \mu \)M of human recombinant annexin I. Annexin I binding sites were detected by sequential incubation with 60 \( \mu \)g/ml annexin I monoclonal antibody 1B or matched isotype control mAb, IgG\(_2a\), and FITC-conjugated anti-mouse IgG. Fluorescence was analysed on a MO-FLO flow cytometer (Cytomation, Ft Collins, CO). Cells were gated according to forward and right angle scatter, using 10,000 cells for each determination. Each determination was performed in duplicate, with
annexin I binding represented by mean fluorescence intensity.

Assessment of PLA2 activity

PLA2 activity in FLS was determined according to Croxtall et al.22 Briefly, FLS were incubated for 18 h with 1 μCi/ml [3H]arachidonic acid in 0.1% BSA/RPMI. Cells were treated with 0–100 μg/ml annexin I peptide, 0, 0.1 ng/ml human recombinant IL-1β, 10-9–10-7 M DEX for 8 h. Triplicate cultures were used for each determination. Radioactivity in the supernatant was determined using a Wallac 1429 liquid scintillation counter (Pharmacia, Finland), with results expressed as tritiated arachidonic acid released, or as a percentage of the mean result of unstimulated cells.

Determination of PGE2 levels

PGE2 release was determined by assaying treated supernatants, using ELISA. Each determination was performed in duplicate, with results expressed as a percentage of the mean result of the unstimulated cells. The detection limit for this assay was <0.1 ng/ml.

Assessment of COX activity

COX activity was measured according to Wilborn et al.27 In brief, FLS were incubated for 30 min with 10 μM exogenous arachidonic acid. Supernatants were aspirated and assayed for PGE2 content using ELISA. Duplicate cultures were used for each determination. COX activity was expressed as a percentage of the mean result of the unstimulated cells.

Determination of intracellular COX2

Intracellular expression of COX2 in FLS was determined using permeabilization flow cytometry, as described by Morand et al.23 Briefly, cells were fixed by suspension in 2% paraformaldehyde/PBS, followed by permeabilization using 0.2% saponin/PBS. FLS were then sequentially incubated with 20 μg/ml COX2 mAb (or isotype-matched mAb control, IgG1) and FITC-conjugated anti-mouse IgG. Permeabilization of the cells was reversed with PBS. Labelled FLS were analysed using flow cytometry. 10,000 cells were used for each determination. Intracellular COX2 protein was expressed as mean fluorescence intensity after subtraction of mean fluorescence intensity obtained with negative control mAb.

Statistical analysis

Results are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using the Student’s t-test, with values of p<0.05 regarded as statistically significant.

Results

We initially sought to determine the presence of annexin I binding sites on human FLS. Annexin I binding sites as determined by mean fluorescence intensity were detected using a concentration range of annexin I (0–10 μM). Results demonstrated concentration-dependent annexin I binding, with more than 99% of cells demonstrating annexin I binding at 10 μM (Fig. 1, Table 1).

To define the effect of annexin I on synoviocyte PLA2 activity, FLS were treated with annexin I N-terminal peptide ac 2–26 (0–100 μg/ml). Annexin I peptide induced a significant concentration-dependent inhibition of constitutive PLA2 activity (Fig. 2(a)).

Table 1. Annexin I binding sites on human FLS

| Annexin I concentration (μM) | Annexin I binding (%) | p value |
|-----------------------------|-----------------------|---------|
| 0                           | 3.7 ± 0.5             |         |
| 1                           | 76.7 ± 4.2            | < 0.01  |
| 5                           | 97.0 ± 0.4            | < 0.01  |
| 10                          | 99.5 ± 0.1            | < 0.01  |

Annexin I binding on FLS was detected using a concentration range of annexin I (0–10 μM) and quantitated by flow cytometry. Values are the percentage of cells expressing fluorescence greater than that obtained with a negative control mAb, and are the mean ± SEM of 6 experiments. All concentrations of annexin I exhibited significant binding (p<0.01) compared to cells incubated without annexin I.
Inhibition of PLA₂ activity by annexin I was reversed when cells were co-stimulated with IL-1β (Fig. 2(b)). We subsequently assessed the effects of DEX on synoviocyte PLA₂ activity. DEX treatment did not significantly inhibit constitutive PLA₂ activity over the concentration range 10⁻⁹–10⁻⁷ M. In contrast, DEX exerted a significant concentration-dependent reduction of PLA₂ activity in IL-1β-stimulated FLS (Fig. 3).

Since annexin I peptide inhibited constitutive PLA₂ activity, we next determined whether treatment with annexin I peptide affected PGE₂ release. Constitutive PGE₂ synthesis was detected in FLS. Annexin I peptide did not significantly reduce constitutive PGE₂ synthesis (Fig. 4(a)). A significant increase in PGE₂ release was observed following IL-1β stimulation (p = 0.001), and annexin I peptide did not inhibit IL-1β-stimulated PGE₂ release. In contrast, DEX had no effect on constitutive PGE₂ release but significantly inhibited IL-1β-induced PGE₂ release in a concentration-dependent manner (Fig. 4(b)).

To further address the differential inhibitory actions of annexin I on PLA₂ activity and PGE₂ synthesis, studies were designed to evaluate the effects of annexin I peptide and DEX on constitutive and IL-1β-induced synoviocyte COX activity. Since the synthesis of PGE₂ from endogenous arachidonic acid results

---

FIG. 2. Effect of annexin I peptide on human FLS PLA₂ activity. FLS were treated with (a) annexin I ac 2-26 (0–100 µg/ml), and/or (b) IL-1β (0.1 ng/ml) plus annexin I peptide for 8 h. PLA₂ activity is expressed as ³H-AA released. Values are the mean ± SEM of 8 experiments. *p < 0.05 versus untreated FLS, †p < 0.01 versus untreated FLS.

FIG. 3. Effect of DEX on human FLS PLA₂ activity. FLS were treated with DEX (10⁻⁹–10⁻⁷ M), and/or IL-1β (0.1 ng/ml) for 8 h. PLA₂ activity (³H-AA released) is expressed as a percentage of untreated FLS. Values are the mean ± SEM of 8 experiments. *p < 0.05 versus untreated FLS, †p < 0.01 versus IL-1β-treated FLS.

FIG. 4. PGE₂ release in human FLS. Human FLS were treated with IL-1β (0.1 ng/ml), and/or (a) annexin I ac 2-26 (100 µg/ml), (b) DEX (10⁻⁹–10⁻⁷ M) for 8 h. PGE₂ release was quantitated by assaying supernatants using ELISA and expressed as a percentage relative to untreated FLS. Values are the mean ± SEM of 4 experiments. *p < 0.01 versus untreated FLS, †p < 0.05 versus IL-1β-treated FLS.
from the activities of both PLA\textsubscript{2} and COX, to estimate maximal COX activity, PLA\textsubscript{2} activity was bypassed by addition of exogenous arachidonic acid.\textsuperscript{7} Low levels of constitutive COX activity were detected in FLS. IL-1\textbeta significantly increased COX activity ($p = 0.0004$) (Fig. 5(a)). Annexin I peptide exerted no significant effect on constitutive or IL-1\textbeta-stimulated COX activity (Fig. 5(a)). DEX exerted no significant effect on constitutive COX activity in DEX treated FLS. In contrast, DEX resulted in a concentration-dependent reduction of IL-1\textbeta-induced COX activity (Fig. 5(b)). These results demonstrate consistency between modulation of intracellular expression of COX2 and its activity.

**Discussion**

The hypothesis that annexin I is an anti-inflammatory mediator in arthritis originated from the detection of annexin I in human rheumatoid synovium.\textsuperscript{24} Animal models of arthritis have subsequently demonstrated that annexin has important inhibitory effects *in vivo*. For example, administration of annexin I peptide substantially inhibited carrageenan-induced arthritis, whilst anti-annexin I antibody exacerbated arthritis severity and reversed the effect of exogenous DEX in this model.\textsuperscript{12} Similarly, exacerbation of disease and increased synovial production of tumour necrosis factor-\alpha and PGE\textsubscript{2} were observed in adjuvant arthritic rats administered anti-annexin I antibody.\textsuperscript{13} Moreover, annexin I neutralization reversed the effects of DEX on disease severity in adjuvant arthritis\textsuperscript{13} and on rat synovial macrophage nitric oxide production.\textsuperscript{11} In human disease, histological studies demonstrate
Given that annexin I is expressed in RA synovium, it is conceivable that in FLS, annexin I mediates its biological effects through specific cell surface annexin I binding sites on leukocytes compared to controls.\textsuperscript{25} Impaired glucocorticoid induction of annexin I production has also been noted in leukocytes of RA patients,\textsuperscript{26} and RA patients with high titre anti-annexin I antibodies exhibit impaired glucocorticoid responsiveness.\textsuperscript{27}

Treatment of undifferentiated cells with glucocorticoids increases annexin I transport to the cell surface.\textsuperscript{28} The mechanisms whereby annexin I crosses the membrane are unclear since the protein lacks a signal sequence and is therefore unlikely to access secretory vesicles for release via the conventional method of exocytosis. The translocation of annexin I protein from intracellular stores to cell surface binding sites is believed to be imperative for its function.\textsuperscript{29,30} Certainly, extracellular anti-annexin I antibodies significantly reverse the anti-inflammatory effects of glucocorticoids and simultaneously deplete intracellular cellular annexin I.\textsuperscript{31-33}

Evidence that exogenous annexin I modulates its biological effects through specific cell surface annexin I binding sites originated from the identification of these sites on peripheral blood leukocytes.\textsuperscript{10} Given that annexin I is expressed in RA synovium, it is conceivable that in FLS, annexin I mediates its biological effects via binding to cell surface sites. No previous study has examined the presence of binding sites or the biological function of annexin I in human synovial cells.

The current data establish the presence of annexin I binding sites on human FLS. The factors influencing annexin I binding site expression are unclear, and the absence of molecular identification of the binding site limits study of its regulation. Nonetheless, having established the presence of potentially biologically active annexin I binding sites in FLS, we sought to assess the effect of annexin I on these cells. An annexin I N-terminal peptide of 25 amino acids, annexin I ac 2–26, has been shown to mimic anti-inflammatory actions of annexin I\textsuperscript{34} including inhibition of arthritis models.\textsuperscript{35} Perretti \textit{et al.} have reported that the biological activity of annexin I ac 2–26 is comparable with that of recombinant human annexin I, albeit at a lower molar potency, and that it requires binding to cell surface binding sites to exert its biological effects.\textsuperscript{36}

Previous investigations have evaluated the effects of glucocorticoids and cytokines on the regulation of PLA\textsubscript{2} and COX at the levels of transcription\textsuperscript{6,35} or translation.\textsuperscript{36} Studies have also compared the level of activity of these enzymes in various cell types, following IL-1\textsuperscript{37} and DEX treatments,\textsuperscript{7} but studies of the rate-limiting step at the enzyme activity level in human FLS have not been undertaken. Our results indicate a significant concentration-dependent inhibition of constitutive but not IL-1β-induced PLA\textsubscript{2} activity by annexin I ac 2–26. In A549 cells, inhibition of arachidonic acid release by annexin I peptide is believed to be mediated through inhibition of the activation of cPLA\textsubscript{2} whereby cPLA\textsubscript{2} is not phosphorylated in the presence of annexin I.\textsuperscript{38} Details of how this is accomplished are still uncertain, but binding site-dependent effects of ac 2–26 are unlikely to relate to the previously proposed 'substrate binding' hypothesis for the effects of annexin I on PLA\textsubscript{2}. The selective inhibitory action of DEX on IL-1β-stimulated but not constitutive cPLA\textsubscript{2} transcription and expression has been described in other investigations\textsuperscript{6,35} but is confirmed at the enzyme activity level for the first time in the current study. The uncoupling of the effects of annexin I and glucocorticoids on PLA\textsubscript{2} supports the contention that the constitutive anti-inflammatory effects of annexin I are only in part related to mediating the effects of glucocorticoids.

As previously demonstrated, constitutive PGE\textsubscript{2} synthesis was detected in cultured FLS. Cytokine upregulation of PGE\textsubscript{2} synthesis was observed, again consistent with previous findings.\textsuperscript{5,36,37} Annexin I peptide did not demonstrate any significant inhibitory effect on constitutive or IL-1-stimulated PGE\textsubscript{2} production. In rat astrocytes, annexin I peptide reduced but did not abolish endotoxin-induced PGE\textsubscript{2} release.\textsuperscript{38} Consistent with its effects on PLA\textsubscript{2} activity, DEX significantly reduced IL-1β-stimulated but not constitutive PGE\textsubscript{2} release.\textsuperscript{7,37,38}

Annexin I mAb, however, has been observed to reverse the effects of DEX inhibition on PGE\textsubscript{2} release, and this study also suggested that glucocorticoid suppression of COX occurs via an annexin I-independent mechanism.\textsuperscript{39}

Glucocorticoid-induced suppression of COX2 appears to be independent of annexin I and is almost certainly explained by the direct interaction of the steroid-receptor complex with nuclear factor-kappa B.\textsuperscript{40} DEX inhibition of cytokine- or mitogen-induced COX regulation has been previously reported.\textsuperscript{6,7,41,42} In this study, regulation of intracellular COX2 expression was found to be consistent with regulation of its activity, suggesting that the level of COX activity is dependent upon intracellular levels of COX2.\textsuperscript{35} The differential effects of annexin I peptide and DEX on PLA\textsubscript{2} activity, COX, and PGE\textsubscript{2} production support the hypothesis that COX is the rate-limiting enzyme in IL-1β-induced PGE\textsubscript{2} synthesis in FLS. In contrast, the lack of effect of glucocorticoids on constitutive PLA\textsubscript{2} and COX2 activity suggests that annexin I may have a glucocorticoid-independent role in constitutive regulation of PLA\textsubscript{2} activity. Biological activity of annexin I peptide has been demonstrated \textit{in vitro} in rat carrageenan arthri-
Accession I effect on synovial fibroblasts

In summary, three novel findings are reported in this study. Firstly, the presence of Accession I binding sites on synovioctyes is demonstrated. Secondly, uncoupling of the effects of Accession I and glucocorticoids on constitutive and cytokine-induced arachidonic acid generation suggests that Accession I has glucocorticoid-independent regulatory activities in inflammation. Our results are consistent with the conclusion that COX2 is the rate-limiting step in synovioctye PGE2 synthesis, suggesting that PLA2-directed strategies may not successfully inhibit eicosanoid production in arthritis. Thirdly, the lack of effect of Accession I on PGE2 synthesis, despite clear effects on inflammation in vivo, suggests the anti-inflammatory effects of Accession I are eicosanoid-independent. For example, Accession I may influence arachidonic acid-mediated intracellular signal transduction. Arachidonic acid influences activation of the Jun-N terminal kinase/stress activated protein kinase subgroups of the membrane activated protein kinase family of signal transduction enzymes, via an eicosanoid-independent pathway.

ACKNOWLEDGEMENTS: The authors acknowledge support from the National Health & Medical Research Council of Australia (EM).

References

1. Arend WP Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 505–15.
2. Murakami M, Nakatani Y, Natsui G-I, Inoue K, Kudo I. Regulatory functions of PLA2. Crit Rev Immunol 1997; 17: 255–85.
3. Croftell IJ, Wilder RL, Ristimaki AP, et al. Cytoeicosynagenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1, phorbol ester, and corticosteroids. J Clin Invest 1993; 92: 1095–101.
4. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406–9.
5. Croxall JD, Newman SP, Choudhry Q, Flower RJ. The concerted regulation of ePLA2, COX2, and lipocortin 1 expression by IL-1, in A549 cells. Biochem Biophys Res Commun 1996; 220: 491–5.
6. Angel J, Berenbaum F, DeMant C, Neumann W, Maslich J, Fourrier C. Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial involves the activation of cytosolic phospholipase A2 and cytoeicosynagenase-2. Eur J Biochem 1994; 226: 125–31.
7. Wilborn J, Croxall JD, Burchell MD, Konkel SL, Streiter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cytoeicosynagenase-2. J Clin Invest 1995; 95: 1861–8.
8. Flower RJ. Lipocortin. Prog Clin Biol Res 1990; 349: 11–25.
9. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effects of glucocorticoids. Nature 1986; 327: 117–9.
10. Goulidng NJ, Pan L, Wardwell K, Guye VC, Guye PM. Evidence for specific Accession I binding proteins on human monocytes. Biochem J 1996; 316: 593–7.
11. Yang YH, Hutchinson P, Santos L, Morand EF. Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1. Clin Exp Immunol 1998; 111: 117–22.
12. Yang YH, Lueech M, Hutchinson P, Holdworth SR, Morand EF. Anti-inflammatory effect of lipocortin 1 in experimental arthritis. Inflammation 1997; 21: 583–96.
13. Yang YH, Hutchinson P, Morand EF. Inhibitory effects of Accession I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum 1999; 42: 1538–44.
14. Peretti M, Wheller SR, Choudhry Q, Croxall JD, Flower RJ. Selective inhibition of neutrophil function by a peptide derived from lipocortin-1 N-terminus. Biochem Pharmacol 1995; 50: 1047–52.
15. Giga-Hama Y, Tohda H, Okada H, Owada MS, Okamura H, Kumagai H. High-level expression of human lipocortin 1 in the fission yeast Schizosaccharomyces pombe using a novel expression vector. Biotechnology 1994; 12: 400–5.
16. Sakata T, Iwagami S, Tsuruta Y, Suzuki S, Suzuki R. Study of natural lipocortin 1. A potent mediator for macrophage-mediated immunosuppression in tumor-bearing mice. J Immunol 1993; 151: 1964–72.
17. Alman R, Alarcon G, Appelrought D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1991; 34: 505–14.
18. Alman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1049–59.
19. Koch AE, Polverini PJ, Leibovich J. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum 1986; 29: 471–9.
20. Leeuch M, Metz CN, Hall P, et al. Macrophage migration inhibitory factor (MIF) in rheumatoid arthritis: evidence for pro-inflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999; 42: 1601–8.
21. Perretti M, Flower RJ, Goulding NJ. The ability of murine leukocytes to bind lipocortin 1 is lost during acute inflammation. Biochem Biophys Res Commun 1993; 192: 345–50.
22. Croxell JD, Choudhry Q, Tokomoto H, Flower RJ, Lipocortin-1 and the control of arachidonic acid release in cell signalling. Biochem Pharmacol 1995; 50: 665–74.
23. Morand EF, Hutchinson P, Hargreaves A, Goulding NJ, Boyce NW. Detection of intracellular lipocortin-1 in human leukocyte subsets Clin Immunol Immunopathol 1995; 76: 195–202.
24. Goulding NJ, Dixey J, Morand EF, et al. Differential distribution of annexins 4, 11, 46, and VI in synovium. Ann Rheum Dis 1995; 54: 841–5.
25. Goulding NJ, Jeffers CM, Pan L, Ribug WFC, Guye PM. Selective binding of lipocortin 1 (annexin I) to monocytes and neutrophils is decreased in rheumatoid arthritis. Arthritis Rheum 1992; 35: 1395–7.
26. Morand EF, Jeffers CM, Dixey J, Mitra D, Goulding NJ. Impaired glucocorticoid induction of monoclonal leukocyte lipocortin-1 in rheumatoid arthritis. Arthritis Rheum 1994; 37: 207–11.
27. Podgers MR, Goulding NJ, Hall ND, Flower RJ, Maddison PJ. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis. J Rheumatol 1992; 19: 1668–71.
28. Solito E, Nuci S, Parente L. Dexamethasone-induced translocation of lipocortin (annexin I) to the cell membrane of U-937 cells. Br J Pharmacol 1993; 112: 547–8.
29. Taylor AD, Cowell AM, Flower RJ, Buckingaham JC. Lipocortin 1 mediates an early inhibitory action of glucocorticoids on the secretion of ACTH by the rat anterior pituitary gland in vitro. Neuroendocrinology 1993; 58: 436–9.
30. Christian HC, Taylor AD, Flower RJ, Morris JE Buckingham JC. Characterization and localization of lipocortin 1-binding sites on rat anterior pituitary cells by fluorescence-activated cell analysis/sorting and electron microscopy. J Histochem Cytochem 1997; 45: 641–51.
31. Duncan GS, Peers SR, Carey E, Fordler R, Flower RJ. The local anti-inflammatory action of dexamethasone in the rat carrageenan edema model is reversed by an antisense to lipocortin 1. Br J Pharmacol 1993; 108: 62–5.
32. Croxell JD, Flower RJ. Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci USA 1992; 89: 3571–5.
33. Crino G, Cacace A, Sorrentino L, et al. Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. Br J Pharmacol 1993; 108: 573–4.
34. Perrett M, Athwala A, Harris JG, Goulding NJ, Flower RJ. Lipocortin-1 fragments inhibit neutrophil-dependent edema in the mouse. J Immunol 1995; 155: 4506–14.
35. Newton R, Kaitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cytoeicosynagenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 1997; 60: 67–78.
36. Hulikower KI, Wertheimer SJ, Levin W, et al. Interleukin-1b induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. *Arthritis Rheum* 1994; 37:653–61.

37. Szczepanski A, Moatter T, Carley WW, Gerritsen ME. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Inhibition by glucocorticoids. *Arthritis Rheum* 1994; 37:495–503.

38. Pistritto G, Mancuso C, Traingali G, Perretti M, Preziosi P, Navarra P. The relative contribution of constitutive and inducible cyclooxygenase activity to lipopolysaccharide-induced prostaglandin production by primary cultures of rat hypothalamic astrocytes. *Neurosci Lett* 1998; 246:45–8.

39. Newman SP, Flower RJ, Croxtall JD. Dexamethasone suppression of IL-1-, induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells. *Biochem Biophys Res Commun* 1994; 202:931–9.

40. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 1997; 336:1066–71.

41. Kajubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. *J Biol Chem* 1992; 267:7991–4.

42. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. *J Clin Invest* 1990; 85:1375–80.

43. Kajubu D, Reddy S, Fletcher B, Herschman H. Expression of the protein product of the prostaglandin synthase-2/TIS10 gene is mitogen-stimulated Swiss 3T3 cells. *J Biol Chem* 1995; 270:545–50.

44. Rizzo MT, Carlo-Stella C. Arachidonic acid mediates interleukin-1 and tumor necrosis factor-a-induced activation of the c-jun amino-terminal kinases in stromal cells. *Blood* 1996; 88:3792–800.

45. Cui XL, Douglas JG. Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. *Proc Natl Acad Sci USA* 1997; 94:3771–6.

46. Maridonneau-Parini I, Errasfa M, Russo-Marie F. Inhibition of O2 generation by dexamethasone is mimicked by lipocortin-1 in alveolar macrophages. *J Clin Invest* 1989; 85:1936–40.

---

Accepted after revision 17 May 2000